The estimated Net Worth of George V Migausky is at least $3.71 Milión dollars as of 1 December 2023. Mr. Migausky owns over 12,700 units of Immunovant Inc stock worth over $3,189,922 and over the last 9 years he sold IMVT stock worth over $504,571. In addition, he makes $19,464 as Independent Director at Immunovant Inc.
George has made over 2 trades of the Immunovant Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 12,700 units of IMVT stock worth $504,571 on 1 December 2023.
The largest trade he's ever made was selling 12,700 units of Immunovant Inc stock on 1 December 2023 worth over $504,571. On average, George trades about 1,094 units every 46 days since 2016. As of 1 December 2023 he still owns at least 109,808 units of Immunovant Inc stock.
You can see the complete history of Mr. Migausky stock trades at the bottom of the page.
George V. Migausky serves as Independent Director of the Company. From March 2019 until the closing of the Business Combination he served as a member of HSAC’s board of directors. Mr. Migausky has more than 30 years of experience in the life sciences industry, having served as Chief Financial Officer for several public biopharmaceutical and clinical diagnostic companies. In 2017, Mr. Migausky served as interim Chief Financial Officer for Ocular Therapeutix, Inc. Prior to that, he served as Executive Vice President and Chief Financial Officer of Dyax Corp. a position he held from 2008 through the company’s acquisition by Shire for $6.4 billion in 2016. Before joining Dyax, Mr. Migausky served as Chief Financial Officer of Wellstat Management Company from 2007 to 2008; and Chief Financial Officer of IGEN International and BioVeris Corporation from 1986 through their acquisitions by F. Hoffman LaRoche in 2004 and 2007, respectively. Current directorships include Abeona Therapeutics Inc., where he also serves as Chair of the audit committee, a position he has held since 2020, Hyperion Catalysis International, a position he has held since 2008, and the Massachusetts Eye and Ear Institute, where he has served as a trustee since 2015. Mr. Migausky has previously served on the board of directors as Chair of the audit committee at Dimension Therapeutics, a position he held from 2015 until the company was acquired in 2017. Mr. Migausky received his BS from Boston College and his MBA from Babson College. Our board of directors believes that Mr. Migausky’s qualifications to sit on our board include his experience both in the capacity of an executive as well as a director, along with his expertise in strategic planning, corporate financing and financial reporting, business development and human resources.
As the Independent Director of Immunovant Inc, the total compensation of George Migausky at Immunovant Inc is $19,464. There are 9 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
George Migausky is 63, he's been the Independent Director of Immunovant Inc since 2019. There are 1 older and 13 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
George's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann a Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: